CORDIS · 965193 · H2020
DECIDER Improved clinical decisions via integrating multiple data levels to overcome chemotherapy resistance in high-grade serous ovarian cancer
Coordinator: HELSINGIN YLIOPISTO (FI)
The goals of this inter-disciplinary project are to 1) gain understanding of the mechanisms causing chemoresistance in high-grade serous ovarian cancer (HGSOC) patients, 2) deliver tools that enable effective and cost-efficient personalised treatment options for HGSOC patients, and 3) commercialise predictive kits & software for treatment response prediction and finding the right therapeutic regimen to the right patient. This project takes an advantage on prospectively and longitudinally collected fresh and blood specimens of HGSOC patients. Longitudinal, multi-layer data are analysed with ML…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €15.0M awarded to the consortium. The project runs over approximately 5.5 years from 2021-02-01 to 2026-07-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from FI
see all →- BalticSeaH2 — Cross-border Hydrogen Valley around the Baltic Sea101112047 · HORIZON · €25.0M
- R4C — Regions4Climate101093873 · HORIZON · €24.5M
- LUMI-IQ — LUMI AI Factory - Advanced experimental AI-optimised quantum based platform101239031 · HORIZON · €20.0M
- SPARCs — Sustainable energy Positive & zero cARbon CommunitieS864242 · H2020 · €19.7M
- Qu-Pilot — Experimental production capabilities for quantum technologies in Europe101113983 · HORIZON · €19.0M
- EUDAT2020 — EUDAT2020654065 · H2020 · €18.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €15.0M toward a total project budget of €15.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-SC1-BHC-2018-2020.
- Who coordinates the project?
- The project is coordinated by HELSINGIN YLIOPISTO (FI).
- What is the project timeline?
- The project runs from 2021-02-01 to 2026-07-31 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 965193.